New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
07:55 EDTATRS, ATRS, BDX, BDX, ANTH, ANTH, NKTR, NKTR, SSH, SSH, IDRA, IDRA, LXRX, LXRX, ARAY, ARAY, ABBV, ABBV, INFI, INFI, JAZZ, JAZZ, IMMU, IMMUCowen to host a conference
34th Annual Global Healthcare Conference is being held in Boston on March 3-5 with webcasted company presentations to begin on March 5 at 8:00 am; not all company presentations may be webcasted. Webcast Link
News For ATRS;JAZZ;INFI;ABBV;ARAY;LXRX;IDRA;SSH;NKTR;ANTH;BDX;IMMU From The Last 14 Days
Check below for free stories on ATRS;JAZZ;INFI;ABBV;ARAY;LXRX;IDRA;SSH;NKTR;ANTH;BDX;IMMU the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 19, 2014
08:27 EDTLXRXLexicon downgraded to Hold from Buy at Gabelli
Subscribe for More Information
07:20 EDTJAZZJazz Pharmaceuticals initiated with an Overweight at JPMorgan
Subscribe for More Information
August 18, 2014
11:41 EDTJAZZCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 15, 2014
08:11 EDTJAZZJazz Pharmaceuticals management meeting strengthens postive view, says Cowen
Subscribe for More Information
August 12, 2014
15:53 EDTJAZZCanaccord to hold a conference
34th Annual Growth Conference to be held in Boston on August 13-14.
07:36 EDTIDRAIdera Pharmaceuticals says 'well capitalized' to execute current business goals
Subscribe for More Information
07:31 EDTIDRAIdera Pharmaceuticals reports Q2 EPS (10c), consensus (9c)
Subscribe for More Information
05:39 EDTSSHSunshine Heart reports Q2 EPS (38c), consensus (40c)
Reports Q2 revenue $0, consensus $130,000.
August 8, 2014
07:48 EDTABBVCredit Suisse remains a buyer of AbbVie
Subscribe for More Information
August 7, 2014
08:14 EDTIDRAIdera Pharmaceuticals announces collaboration with TMA
Subscribe for More Information
07:39 EDTNKTRNektar management to meet with Brean Capital
Subscribe for More Information
07:19 EDTLXRXLexicon reports Q2 EPS (5c), consensus (5c)
Reports Q2 revenue $700K, consensus $120.00K.
07:12 EDTATRSAntares Pharma reports Q2 EPS (7c), consensus (7c)
Reports Q2 revenue $6.33M, consensus $6.43M.
August 6, 2014
12:59 EDTABBVCovidien drops as Treasury explores ways to stymie inversions
Shares of medical device and drug maker Covidien (COV) are falling after multiple media outlets reported that the Treasury Department is looking into ways of curtailing tax inversion deals. Covidien has agreed to be acquired by Medtronic (MDT) in a tax inversion deal. BACKGROUND: Tax inversions refer to an acquisition of one company, usually officially based in a country in Europe or elsewhere, by a U.S. company, following which the acquiring company becomes domiciled in the same country as the company that it bought. The switch has the potential to significantly lower the acquiring company's tax rate. WHAT'S NEW: The Treasury Department is looking at options that would enable the Obama administration to curtail inversion deals without authorization from Congress, multiple media outlets reported last night and today. ANALYST REACTION: In a note to investors today, Wells Fargo analyst Larry Biegelsen wrote that he believes that Medtronic would buy Covidien even if the transaction cannot be done as an inversion. At a conference in June, Medtronic CFO Gary Ellis said that his company would "do the deal whether it's an inversion or not inversion," Biegelsen stated. If no inversion is possible, Medtronic would respond by using less of its stock and more debt to fund the transaction, the analyst believes. Such a change would actually cause Medtronic's cash earnings per share to be higher in the first and second year after the deal than under the current structure, the analyst indicated. He kept an Outperform rating on Medtronic. PRICE ACTION: In early afternoon trading, Covidien dropped 2% to $84.50 and Medtronic fell 1% to $61.50. Meanwhile, drug maker Shire (SHPG), which has agreed to merge with its peer AbbVie (ABBV) in a tax inversion deal, is falling 4% to $236.
10:00 EDTINFIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTJAZZJazz Pharmaceuticals thesis remains intact, says Cowen
Subscribe for More Information
08:51 EDTINFIInfinity Pharma new royalty option facilitates partnership, says RBC Capital
Subscribe for More Information
08:40 EDTABBVShire drops 5% with tax inversions in focus
Subscribe for More Information
08:21 EDTIDRAIdera Pharmaceuticals announces GSOs publication
Subscribe for More Information
08:21 EDTINFIInfinity Pharmaceuticals upgraded to Outperform at William Blair
William Blair upgraded Infinity Pharmaceuticals to Outperform from Market Perform following the company's Q2 results but lowered its price target for shares to $14.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use